For ValueAct, There is Life After Valeant

The activist hedge fund’s 2017 performance was buoyed by a large position in Twenty-First Century Fox.

Jeffrey Ubben, ValueAct Capital

ValueAct Capital continues to thrive despite holding onto Valeant Pharmaceuticals, the troubled drug company whose stock crashed spectacularly in the fall of 2015, and hasn’t recovered since.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.